Slingshot members are tracking this corporate initiative:
Alexion (ALXN) And Eidos' (EIDX) subsidiary - BridgeBio (BBIO) Agree On Eidos’ Transthyretin Amyloidosis (ATTR) Investigational Medicine License
Do you think this event is important to the companies below? How will it affect their stock price?
- Eidos to receive upfront payment of $25 million and equity investment of $25 million, with potential for additional Japanese-based milestone- & royalty-dependent payments -
Slingshot Insights Explained
Strategic Initiative Date
Announcement Date: Sep 09, 2019 Projected Implementation: Q3, 2019 Relevance Tracked Until: Q4, 2019
Don’t see a project related to the strategic initiative you care about?
Related Keywords Amyloidosis, Attr Amyloidosis, Ag10